Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2026-06-01 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Share Issue/Capital Change Classification · 92% confidence The document is a monthly return (Form FF301) filed under HKEX Listing Rules Chapter 19B, detailing authorized/issued share capital movements, public float confirmation, and related confirmations. It is not an earnings release or management discussion, but a regulatory announcement of capital changes and share movements. This fits the Share Issue/Capital Change category (SHA), which covers announcements of share capital movements and issuances.
2026-06-01 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'Articles of Association' for Lepu Biopharma Co., Ltd. It contains detailed chapters on company governance, share issuance, board of directors, management, financial accounting system, and other corporate governance matters. The content is a legal and regulatory framework document governing the company's internal rules, board structure, shareholder rights, and management organization. It is not a financial report, earnings release, or announcement but a governance document. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains the full text of the Articles of Association, not just an announcement or summary.
2026-05-19 English
(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 19, 2026; (2) APPOINTMENT OF SUPERVISOR; (3) CHANGE OF REGISTERED ADDRESS AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results of the 2025 Annual General Meeting (AGM) held on May 19, 2026. It includes details on resolutions passed, appointment of a supervisor, change of registered address, and amendments to the Articles of Association. The text explicitly states it is an announcement of the AGM results and related corporate actions, not the full AGM materials or reports themselves. The document length is 7,816 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Lepu Biopharma Co., Ltd. It details authorized share capital, issued shares, public float sufficiency confirmation, and confirms compliance with listing rules. The document is a regulatory submission about share capital and share movements, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive data about share capital and confirmations. The document fits the category of Regulatory Filings (RNS) as it is a compliance filing related to listing rules and share capital movements without being a financial report or announcement of voting results or capital changes.
2026-05-07 English
DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER
Regulatory Filings Classification · 95% confidence The document is an announcement from Lepu Biopharma Co., Ltd. regarding the dis-application of certain listing rules (Rules 18A.09 to 18A.11) by the Hong Kong Stock Exchange and the removal of the 'B' stock marker. It details the reasons for this change, including market capitalization and revenue tests, and the effects on the company's stock short name and share certificates. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about changes in listing status and stock marker. It is not an annual report, interim report, or earnings release. It is also not a board or management change announcement, nor a voting result or capital change. The document fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement that does not fit other specific categories.
2026-05-06 English
(1) PROPOSED APPOINTMENT OF SUPERVISOR; (2) PROPOSED CHANGE OF REGISTERED ADDRESS; AND (3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
Board/Management Information Classification · 95% confidence The document is an official announcement on the Hong Kong Stock Exchange concerning the proposed appointment of a supervisor (a board-level position), a change of registered address, and amendments to the Articles of Association. It details the biography of the proposed supervisor, terms of office, and governance changes. This fits Squarely under “Board/Management Information” (Code: MANG), as it announces changes in the company’s supervisory board and governance structure rather than presenting full financial results or requesting shareholder votes via proxy materials.
2026-04-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.